Join us as AMCP Market Insights shares exclusive findings from our recent multi-stakeholder expert roundtable on treatment-resistant depression. This webinar will break down payer perspectives on clinical data, address the looming provider network shortage, and outline actionable strategies to prepare your behavioral health network for these emerging interventional treatments. Attendees will walk away with concrete recommendations on removing care barriers, updating coverage frameworks, and driving cross-industry collaboration to evaluate, cover, and operationalize these therapies safely and effectively.

The intersection of population health and managed care pharmacy becomes clearer when viewed through real-world application. Building from foundational concepts introduced in the first webinar, this session explores how population health principles are implemented across diverse settings, including employer groups, health plans, research organizations, and healthcare systems. Through case studies and practical examples, speakers will demonstrate how professionals with different roles and titles contribute to shared goals of improving health outcomes, enhancing patient experiences, and optimizing healthcare resources. Attendees will gain insight into how population health strategies are translated into action and discover opportunities to apply similar approaches within their own organizations. 

This webinar brings together a clinical genetics expert and a managed care medical director to examine Barth syndrome, its mitochondrial mechanism, and the evidence supporting elamipretide, alongside a candid discussion of the coverage and access questions ultra-rare therapies raise—from label interpretation and natural history comparators to value-based contracting and the broader question of how innovation in ultra-rare disease is funded. Participants will leave with a clearer understanding of how clinical realities in rare disease intersect with coverage policy, and where collaboration among manufacturers, clinicians, and payers can improve diagnosis, equitable access, and patient care.

11-11:45am: AI's Defining Question: Humans In, On, or Out of the Loop?

2-3pm: Building Trust in AI: Governance Strategies for Managed Care Pharmacy

4-5pm: Satellite Symposium: Reducing Nonadherence and Rehospitalization Through Effective Tardive Dyskenisia Treatment

A Pre-Approval Information Exchange (PIE) Webinar, presented by Capricor Therapeutics.

Join this AMCP PIE webinar for an overview of deramiocel, an investigational therapy under FDA review for Duchenne muscular dystrophy (DMD). The session will review DMD disease burden, unmet needs in upper-limb and cardiac function, and available pre-approval clinical, safety, and administration information to support payer and formulary planning.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Science & Innovation Webinar, presented by Sanofi.

This webinar will examine the long-term safety profile of efanesoctocog alfa in hemophilia A, drawing upon evidence from clinical studies and emerging real-world experience. Expert faculty will review key safety and efficacy outcomes with long-term treatment experience, and practical considerations relevant to patient management. The session will also explore how real-world utilization and outcomes complement clinical trial findings to provide a more comprehensive understanding of the therapy's performance in routine care. Attendees will gain insights into the evolving evidence base supporting treatment decisions for patients with hemophilia A.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Incyte.

This PIE webinar on tafasitamab-cxix + lenalidomide + R-CHOP in Frontline DLBCL will cover disease state and epidemiology, the current treatment landscape, and key clinical/safety data, followed by a brief Q&A

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Revolution Medicines.

Revolution Medicines will present results from the Phase 3 RASolute 302 study evaluating daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, in previously treated patients with metastatic pancreatic adenocarcinoma (PDAC). The PIE presentation will feature an overview of PDAC disease background, current second-line standard of care, and RASolute 302 study design elements and data.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.